Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Mounjaro 5mg KwikPen delivers a single 5mg dose in a fixed number of clicks — typically four clicks, one per week, until the pen is empty. Each weekly injection uses all four clicks in sequence; there is no half-dose, no splitting, and no adjustment of the click count without prescriber instruction. These are prescription-only medicines, so anything beyond understanding your pen's mechanics should be discussed with your prescriber or confirmed in the Patient Information Leaflet.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The KwikPen is a pre-filled, pre-set device. Unlike some insulin pens where you dial up a dose, the Mounjaro pen is factory-set to your prescribed strength. When you inject, you press the button until it can go no further, the click or clicks you hear and feel confirm that the plunger has completed its travel and the full dose has been delivered. You cannot dial down to half a dose or double up by pressing twice.
A widely circulated Mounjaro dose chart by clicks maps this out across all pen strengths. For the 5mg pen, the mechanism is identical to every other strength in the range: one injection, one full dose. The chart is most useful as a quick reassurance that you heard what you expected to hear, it is not a tool for adjusting how much you receive.
If the button did not travel fully, if medicine appeared around the injection site, or if something felt wrong, that is a conversation for your prescriber or the Lilly support line, not something to troubleshoot by changing your click count. The 5mg dose overview covers what to do if you suspect a missed or incomplete injection.
Treatment begins at 2.5mg. That first pen's job is to let your body adjust to tirzepatide's effects on gastric emptying and appetite, at that starting strength, therapeutic weight loss is not the primary goal. After roughly four weeks, a prescriber reviews your response and, if you have tolerated the starter dose reasonably well, moves you to 5mg.
The 5mg step is the first dose at which many people begin to notice meaningful appetite change. It is still part of the escalation path rather than a ceiling; the licensed strengths run up to 15mg, and a prescriber will weigh up how you are responding before any further increase. If you are weighing up whether 5mg is delivering enough for you, the question of whether 5mg is working depends on individual response, not on the click count.
The British National Formulary's tirzepatide entry confirms the titration sequence and the prescriber's role in deciding when to move between doses, decisions that should never be made by changing how you use the pen. You can check the BNF entry for tirzepatide for the professional summary.
If you have been searching for a click chart specifically because you want to compare 5mg with what comes next, that context is worth having. The pen mechanism is the same across the range, so the chart itself does not change in character as you move up, what changes is the volume of medicine delivered and, over time, the degree of appetite suppression and potential for weight loss.
Clinical trial data published in the New England Journal of Medicine (SURMOUNT-1) showed that average weight reduction at 15mg over 72 weeks was around 20 to 21%, with the higher doses consistently outperforming the lower ones in the programme. A 15mg click chart follows the same format and mechanics; the 7.5mg pen sits in between. The relevant question for most people at 5mg is not how the pen compares to the 15mg device, but whether their prescriber thinks escalation is appropriate yet.
There is also a broader Mounjaro dose chart covering the full licensed schedule, which puts the 5mg step in context across the whole treatment arc.
People often reach for the click chart not because the pen malfunctioned, but because they are uncertain whether they are doing something right. That uncertainty usually reflects a gap in the support around their treatment. A well-run service checks in before every dose increase, reviews your response to the current pen, and gives you somewhere to ask exactly this kind of question without waiting for a GP slot.
If you are managing your treatment privately and feel unsure about any aspect of your current dose, it is worth reviewing what aftercare your provider actually offers, our clinical team is available seven days a week for that kind of support. For anyone still deciding whether to start, the treatment overview sets out what the assessment involves. And if cost is part of the calculation, the picture has shifted since Eli Lilly adjusted UK list prices in 2025, which our price increase explainer covers in plain terms.
The click chart answers a mechanics question cleanly. The dose itself (whether 5mg is the right place to be, how long to stay there, and what comes next) is a clinical conversation. Check your eligibility and speak to our prescribers if you'd like that conversation to happen the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.